SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

Search

Innate Pharma SA

Slēgts

1.698 -5.67

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.698

Max

1.728

Galvenie mērījumi

By Trading Economics

Ienākumi

-25M

Pārdošana

12M

Peļņas marža

-200.599

Darbinieki

181

EBITDA

-26M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+155.7% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

159M

Iepriekšējā atvēršanas cena

7.37

Iepriekšējā slēgšanas cena

1.698

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Innate Pharma SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. apr. 22:38 UTC

Karstas akcijas

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

2025. g. 5. apr. 09:30 UTC

Peļņas

Elon Musk's Mr. Fix-It Takes Center Stage During a Really Bad Week -- WSJ

2025. g. 5. apr. 01:00 UTC

Iegādes, apvienošanās, pārņemšana

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ

2025. g. 5. apr. 01:00 UTC

Iegādes, apvienošanās, pārņemšana

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ -2-

2025. g. 4. apr. 21:53 UTC

Tirgus saruna

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

2025. g. 4. apr. 21:44 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

2025. g. 4. apr. 21:00 UTC

Top Ziņas

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

2025. g. 4. apr. 20:52 UTC

Tirgus saruna

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

2025. g. 4. apr. 20:52 UTC

Top Ziņas

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

2025. g. 4. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. apr. 20:48 UTC

Top Ziņas

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

2025. g. 4. apr. 20:45 UTC

Top Ziņas

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

2025. g. 4. apr. 20:32 UTC

Top Ziņas

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

2025. g. 4. apr. 20:21 UTC

Top Ziņas

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

2025. g. 4. apr. 20:00 UTC

Top Ziņas

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

2025. g. 4. apr. 19:51 UTC

Tirgus saruna

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

2025. g. 4. apr. 19:37 UTC

Top Ziņas

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

2025. g. 4. apr. 19:32 UTC

Tirgus saruna

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

2025. g. 4. apr. 19:28 UTC

Top Ziņas

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

2025. g. 4. apr. 19:15 UTC

Tirgus saruna

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

2025. g. 4. apr. 19:12 UTC

Top Ziņas

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

2025. g. 4. apr. 19:11 UTC

Tirgus saruna

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

2025. g. 4. apr. 19:09 UTC

Tirgus saruna

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

2025. g. 4. apr. 19:09 UTC

Top Ziņas

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

2025. g. 4. apr. 19:00 UTC

Tirgus saruna

Fed Has Limited Options to Counter Tariffs -- Market Talk

2025. g. 4. apr. 18:53 UTC

Tirgus saruna

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

2025. g. 4. apr. 18:51 UTC

Tirgus saruna

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

2025. g. 4. apr. 18:44 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 4. apr. 18:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 4. apr. 18:44 UTC

Tirgus saruna

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

Salīdzinājums

Cenas izmaiņa

Innate Pharma SA Prognoze

Cenas mērķis

By TipRanks

155.7% augšup

Prognoze 12 mēnešiem

Vidējais 4.398 EUR  155.7%

Augstākais 5.7 EUR

Zemākais 3.1 EUR

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Innate Pharma SA — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

1

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 1.854Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.